Nuvelo Announces Results from Phase 3 NAPA Program in Acute Peripheral Arterial Occlusion

- Webcast to Be Held at 4:30 p.m. ET today to Discuss Results -

SAN CARLOS, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced results from the Phase 3 NAPA (Novel Arterial Perfusion with Alfimeprase) program evaluating alfimeprase in acute peripheral arterial occlusion (PAO). Alfimeprase is the company's lead product candidate and is currently being studied in acute ischemic stroke and catheter occlusion (CO). The NAPA data were presented in a poster session by Fred Weaver, M.D., professor of surgery and associate director of the University of Southern California Cardiovascular and Thoracic Institute, at the 2008 International Symposium on Endovascular Therapy (ISET), taking place this week in Hollywood, FL. A webcast will be held today, January 24, 2008, at 4:30 p.m. ET to review these data.

In the NAPA-2 clinical trial, the primary endpoint of 30-day open vascular surgery avoidance was achieved in 34.9 percent of patients receiving alfimeprase, 37.2 percent of patients receiving intra-thrombus (IT) placebo, and 18.4 percent of patients receiving peri-thrombus (PT) placebo. An interim analysis of the NAPA-3 study shows that 30-day open vascular surgery avoidance was achieved in 29.4 percent of patients receiving alfimeprase and 17.6 percent of patients receiving IT placebo. Efficacy data from subjects with longer clots or smaller drops in alpha-2 macroglobulin, which rapidly and irreversibly inactivates alfimeprase, suggest improved retention of alfimeprase at the site of the clot might improve lysis. Overall adverse events (AE), as well as rates of hypotension and peripheral embolism, were numerically higher among patients receiving alfimeprase in both studies. However, serious adverse events (SAE), major hemorrhage, cardiac events and infections were higher in subjects receiving alfimeprase in NAPA-2, but were higher in subject receiving IT placebo in NAPA-3. No intracranial hemorrhages were reported in either study.

"We continue to believe that alfimeprase is an active thrombolytic agent when delivered in an optimized fashion, and we are focused on developing alfimeprase in stroke and catheter occlusion," said Michael Levy, M.D., executive vice president of research and development for Nuvelo. "We continue to enroll patients in Phase 2 clinical trials in both these indications and expect top-line data from the SONOMA-3 catheter occlusion trial in the first half of 2008."

NAPA Phase 3 Program Details

The NAPA Phase 3 Program consisted of two randomized, double-blind studies evaluating the efficacy and safety of 0.3 mg/kg of alfimeprase in patients with acute PAO with symptom onset within 14 days. In NAPA-2, subjects were randomized in a 4:3:1 ratio to receive IT alfimeprase (n=149), IT placebo (n=113), or PT placebo (n=38). In NAPA-3, subjects were randomized 1:1 between alfimeprase (n=51) and IT placebo (n=51). The primary endpoint of both studies was avoidance of open vascular surgery within 30 days of treatment. A variety of secondary endpoints were also evaluated, including restoration of arterial blood flow, safety endpoints such as the incidence of bleeding, and pharmacoeconomic endpoints such as length of hospital and intensive care unit stay.

Webcast Call Information

Nuvelo will hold a conference call Thursday, January 24th at 4:30 p.m. Eastern Time to discuss this presentation. To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode 31293129. A telephone replay of the conference call will be available through Thursday, February 7, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode 31293129.

In addition, this call is being webcast by Thomson/CCBN and can be accessed via Nuvelo's website at The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (, a password-protected event management site.

About Alfimeprase

Alfimeprase is a recombinant direct acting fibrinolytic (rDAF) that has the potential to rapidly dissolve blood clots through a unique mechanism of action -- it directly degrades fibrin, a protein that provides the scaffolding for blood clots. In addition, alfimeprase's thrombolytic activity appears to be localized to the site of delivery because it is rapidly inactivated by alpha-2 macroglobulin, a naturally occurring protein in the blood, as it moves away from the site of delivery and into the general blood circulation.

Alfimeprase is currently being evaluated in Phase 2 studies as a potential treatment for catheter occlusion and acute ischemic stroke.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; and preclinical candidates NU172, a thrombin inhibitor for use as a potential direct and short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and research programs, the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; stock market conditions; the impact of competitive products and technological changes; and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10Q for the quarter ended September 30, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

CONTACT: Lee Bendekgey, SVP, CFO and General Counsel of Nuvelo, Inc.,+1-650-517-8358, ; or Nicole Foderaro of WeissCommPartners, +1-415-946-1058, , for Nuvelo, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:NUVO)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: January 2008

View comments